Chapter 24 — Further Reading

A note before the list. This is a subject area where search results are dominated by two kinds of source that are almost useless to you: marketing copy written by sellers, and forum discussion written by users. Neither is evidence. The tiers below are organized so that you can start with material that is authoritative and freely available and only descend into the primary literature if you want to.

Where the primary sources live. For any approved drug, the single most information-dense document is the regulatory product label — the FDA prescribing information in the United States, the EMA summary of product characteristics in Europe. Labels are public, free, and contain the indication, the studied population, the trial results, and the complete adverse-effect table. For a chapter like this one, the label is worth more than most review articles.

Tier 1 — Start here

The regulatory labels themselves. Look up the prescribing information for bremelanotide and for afamelanotide. Read three sections in each: the Indications and Usage section (note how narrow it is, and note the exclusions), the Clinical Studies section (this is where the trial design and the effect sizes live, reported by the regulator rather than by a press release), and the Adverse Reactions table. Then compare what you read against how the drug is described in consumer coverage. This exercise is the fastest calibration available anywhere in this book.

A general endocrinology or pharmacology textbook chapter on the melanocortin system. Any standard text will give you MC1R through MC5R, POMC processing, and the agouti-related peptide relationship, in about ten pages. The receptor map is the durable content of this chapter, and a textbook treatment is better than any review aimed at a single indication.

Patient-organization material on erythropoietic protoporphyria. Rare-disease patient organizations publish descriptions of what EPP actually is like to live with, and reading one changes how you evaluate afamelanotide's approval. A drug that increases pain-free time outdoors reads very differently once you understand what the alternative is.

A dermatology society or public health authority statement on unregulated tanning peptides. Several national dermatology bodies and drug regulators have issued public warnings about melanotan II. These are short, they cite the case-report literature, and they are written by people whose job is skin cancer.

Tier 2 — Go deeper

The pivotal bremelanotide trial publications. Two randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD. Read them for the instrument choice, the co-primary endpoints, the placebo-arm movement, the discontinuation rates, and the secondary endpoint on satisfying sexual events. Search a bibliographic database for bremelanotide plus hypoactive sexual desire disorder; the trials are indexed and the results are also summarized in the regulatory review documents.

The FDA advisory committee materials and review documents. For drugs where an advisory committee met, the briefing documents and transcripts are public and are extraordinary teaching material — you get the sponsor's case, the agency's analysis, and a room full of experts arguing about whether an effect size is meaningful. This is the single best window available into how "modest but significant" gets adjudicated in practice.

The afamelanotide EPP trial literature. Randomized controlled trials with pain-free sunlight exposure as the endpoint. Worth reading for how you design a trial when the outcome is "how long can this person be outside," which is a harder measurement problem than it first appears.

The melanotan II case-report literature. Search for melanotan plus nevi, plus melanoma, plus eruptive melanocytic. Read several. Then read them again asking the Chapter 5 §5.2 question: what does this set of reports license me to conclude, and what does it not? This is the best available exercise in calibrating a harm signal, precisely because the reports are individually weak and collectively non-trivial.

Review literature on the medicalization debate. The argument over HSDD as a diagnostic category has been conducted in the open, in medical journals, in bioethics literature, and in sociology of medicine. Look for pieces on both sides; the argument is better than either side's summary of the other.

Kisspeptin physiology reviews. Search for kisspeptin plus KISS1R plus reproductive axis. The discovery history — from a receptor with no known ligand, to a set of families with unexplained failure of puberty, to a reorganization of how the field understood the onset of puberty — is one of the better recent stories in endocrinology.

Tier 3 — For the specialist

Structure-activity literature on cyclic melanocortin analogs. If you want to understand why one functional group at the C-terminus shifts subtype selectivity, this is where it lives. Expect medicinal chemistry.

Receptor subtype selectivity and biased signaling at melanocortin receptors. The frontier question in this family is whether you can build agonists that engage MC4R for a central effect without engaging MC1R at all — and, further, whether different signaling pathways downstream of the same receptor can be selectively activated. This is Chapter 33's territory applied to this family.

Pharmacovigilance methodology. If §24.6 interested you, the general literature on signal detection — how spontaneous reports are aggregated, what disproportionality analysis is, why case reports work for rare distinctive harms and fail for common nonspecific ones — is the formal version of Chapter 5 §5.2. It will improve how you read every safety claim you encounter afterward.

Psychometrics of sexual function instruments. Validation, minimal clinically important difference estimation, and the debate over whether questionnaire changes in this domain track anything patients value. Dry, and directly load-bearing for §24.4.

Kisspeptin analogs in assisted reproduction. Early clinical work on upstream triggering. Read for the pulsatility problem and how investigators are attempting to work around it.

If you only do one thing

Pull up the bremelanotide prescribing information and read the Indications and Usage section, then immediately read three consumer articles about the same drug.

Time it — the label section takes about ninety seconds. Note the exact population. Note the exclusions. Then read the coverage and count how many of the boundaries survived the trip. In most cases the answer is none: the hormonal-status restriction disappears, the diagnostic criteria disappear, the distress requirement disappears, the modest effect size becomes "works," and the nausea rate goes unmentioned.

That gap — between what a regulator authorized and what the public understands to have been authorized — is the single most transferable thing in this chapter. It is Field 7 of your dossier, and once you have seen it clearly for one drug, you will see it everywhere.